Search for Clinical Trial Results

Marginal Zone Lymphoma - 25 Studies Found
Status | Study |
Completed |
Study Name: Yttrium Y 90 Ibritumomab Tiuxetan and Rituximab in Treating Patients With Previously Untreated Marginal Zone Lymphoma Condition: Marginal Zone Lymphoma Date: 2007-03-27 Interventions:
|
Active, not recruiting |
Study Name: Involved Field Radiotherapy for Non-gastric Marginal Zone Lymphoma Condition: Non-gastric Marginal Zone Lymphoma Date: 2006-09-14 Interventions: Radiation: Involved Field Radiotherapy The prescribed dose |
Not yet recruiting |
Study Name: A Study of INCB050465 in Subjects With Relapsed or Refractory Marginal Zone Lymphoma (CITADEL-204) Condition:
|
Terminated |
Study Name: Gemcitabine for Marginal Zone Lymphoma Condition:
Date: 2006-06-14 Interventions: Drug: gemcitabine D1 and 8, Gemcitabine 1250mg/m2 + NS 100ml MIV over 30min, every 3 weeks |
Active, not recruiting |
Study Name: Study of the Bruton's Tyrosine Kinase Inhibitor in Subjects With Relapsed/Refractory Marginal Zone Lymphoma Condition:
Date: 2013-10-29 Interventions: Drug: ibrutinib |
Terminated |
Study Name: Epigenetic Modulation in Relapsed/Refractory Follicular Lymphoma and Marginal Zone Lymphoma Condition:
Date: 2010-02-11 Interventions:
|
Active, not recruiting |
Study Name: Bendamustine and Rituximab for the Treatment of Splenic Marginal Zone Lymphoma Condition: Marginal Zone B-cell Lymphoma Date: 2016-07-26 Interventions: Drug: Bendamustine and Rituximab |
Completed |
Study Name: Endomicroscopy and Gastric MALT-lymphoma Condition: MALT-lymphoma Date: 2012-01-08 Interventions:
|
Recruiting |
Study Name: Bendamustine Plus Rituximab (BR) for Relapsed or Progressive Marginal Zone B-cell Lymphoma (MZBCL) Condition: Marginal Zone B-cell Lymphoma Date: 2015-04-05 Interventions: Drug: bendamustine plus rituximab Bendamustine 90mg/m2 IV on days 1-2 up to 6th cycle Rituximab 375mg/m2 |